Singapore, Mar 11, 2010: Sanofi-aventis has completed its acquisition of Chattem, which has now become a wholly-owned subsidiary of the Sanofi-aventis Group.

This acquisition provides new channels for maximizing the potential of converting Sanofi-aventis’ prescription medicines to over-the-counter (OTC) products, beginning with Allegra (fexofenadine hydrochloride), which is expected to be an important growth driver for Sanofi-aventis.

“Chattem’s existing sales, marketing and distribution teams and infrastructure provide a tremendous platform for future conversions of prescription medicines to OTC products in the US, and I'm confident that Chattem will maximize the success of those conversions,” said Mr Christopher A Viehbacher, CEO of Sanofi-aventis.

“The entire Chattem team is excited to serve as the base for Sanofi-aventis’ US consumer healthcare business and looks forward to capturing the significant growth opportunities. This acquisition creates substantial benefits for our employees, customers and the city of Chattanooga,” said Mr Zan Guerry, CEO of Chattem.

 

Chattem, Sanofi-aventis’ US consumer healthcare division, will be headquartered in Chattanooga, Tennessee. Mr Guerry will lead the US consumer healthcare business and he reports to Mr Greg Irace, President and CEO, Sanofi-aventis, US.